Sugi Predict

Sugi Predict / Compounds / SCHEMBL10162263

SCHEMBL10162263

SCHEMBL10162263

CC(=O)C12CCC(CNC(=O)c3cc(C(=O)NCc4ccc(F)c(C(F)(F)F)c4)nc4ncnn34)(CC1)CC2

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 5/20 0.45
▸ ADAMTS4 O75173 1/20 0.45
▸ MMP3 P08254 1/20 0.45
▸ PDE2A O00408 3/20 0.39
▸ P2RX7 Q99572 5/20 0.37
▸ MBOAT4 Q96T53 2/20 0.35
▸ ENPP2 Q13822 1/20 0.35
▸ PTPN7 P35236 1/20 0.35
▸ DUSP3 P51452 1/20 0.35
▸ MMP10 P09238 1/20 0.34
▸ MMP9 P14780 1/20 0.34
▸ MMP8 P22894 1/20 0.34
▸ FPR3 P25089 1/20 0.34
▸ FPR2 P25090 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162242 0.91 MMP13 (0.39) MMP13ADAMTS4MMP3PDE2AMMP10
SCHEMBL10162240 0.90 MMP13 (0.48) MMP13ADAMTS4MMP3PDE2AMMP10
SCHEMBL10162252 0.89 MMP13 (0.40) MMP13PDE2A
SCHEMBL10162264 0.89 PDE2A (0.39) MMP13PDE2AMBOAT4
SCHEMBL10162258 0.89 RIPK1 (0.39) MMP13ADAMTS4MMP3PDE2AMBOAT4
SCHEMBL10162176 0.88 MMP13 (0.44) MMP13ADAMTS4MMP3PDE2AP2RX7
SCHEMBL10162262 0.88 SMN1; SMN2 (0.38) MMP13ALDH1A1
SCHEMBL10162257 0.87 HRH4 (0.46) MMP13MEN1KMT2A
SCHEMBL10162270 0.86 ALDH1A1 (0.33) MMP13ADAMTS4MMP3MMP8MEN1
SCHEMBL10162267 0.86 LMNA (0.39) MMP13PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.